8-氯腺苷和8-氨基腺苷与维奈克拉协同靶向急性髓系白血病中的甲硫氨酸-MAT2A-SAM轴
研究通过RNA-seq发现8-氯腺苷(8CA)和8-氨基腺苷(8AA)显著抑制急性髓系白血病(AML)细胞的半胱氨酸和甲硫氨酸代谢通路,并下调MAT2A基因;质谱分析显示维奈克拉(VEN)降低AML细胞内甲硫氨酸水平。体外和体内实验表明,VEN与8CA或8AA联用协同降低SAM生物合成并有效靶向AML细胞,提示联合方案具有治疗潜力并为已启动的临床试验提供依据。
要点
- 8CA和8AA显著抑制AML细胞的半胱氨酸和甲硫氨酸代谢通路,MAT2A是下调最显著的基因之一。
- VEN显著降低AML细胞内甲硫氨酸水平。
- VEN与8CA或8AA联用在体内外协同降低SAM生物合成并有效靶向AML细胞。
核心结论
- VEN与8CA或8AA联用通过抑制甲硫氨酸-MAT2A-SAM轴协同靶向AML细胞,提示该联合方案具有治疗潜力,并为已启动的临床试验提供依据。
研究设计与样本
- 研究采用RNA-seq和质谱分析,并在体外和体内评估8CA或8AA与VEN联合对AML细胞的作用。
主要发现
- RNA-seq显示8CA和8AA显著抑制AML细胞的半胱氨酸和甲硫氨酸代谢通路,MAT2A是下调最显著的基因之一。
- 质谱分析显示VEN显著降低AML细胞内甲硫氨酸水平。
- VEN与8CA或8AA联用在体内和体外协同降低SAM生物合成并有效靶向AML细胞。
临床怎么用
- 作者认为联合8CA或8AA与VEN通过抑制甲硫氨酸-MAT2A-SAM轴治疗AML具有潜力,并为已启动的临床试验提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeting the metabolic dependencies of acute myeloid leukemia (AML) cells is a promising therapeutical strategy. In particular, the cysteine and methionine metabolism pathway (C/M) is significantly altered in AML cells compared to healthy blood cells. Moreover, methionine has been identified as one of the dominant amino acid dependencies of AML cells. Through RNA-seq, we found that the two nucleoside analogs 8-chloro-adenosine (8CA) and 8-amino-adenosine (8AA) significantly suppress the C/M pathway in AML cells, and methionine-adenosyltransferase-2A (MAT2A) is one of most significantly downregulated genes. Additionally, mass spectrometry analysis revealed that Venetoclax (VEN), a BCL-2 inhibitor recently approved by the FDA for AML treatment, significantly decreases the intracellular level of methionine in AML cells. Based on these findings, we hypothesized that combining 8CA or 8AA with VEN can efficiently target the Methionine-MAT2A-S-adenosyl-methionine (SAM) axis in AML. Our results demonstrate that VEN and 8CA/8AA synergistically decrease the SAM biosynthesis and effectively target AML cells both in vivo and in vitro. These findings suggest the promising potential of combining 8CA/8AA and VEN for AML treatment by inhibiting Methionine-MAT2A-SAM axis and provide a strong rationale for our recently activated clinical trial.
引用
- Guo J, Buettner R, Du L, et al. 8-Cl-Ado and 8-NH2-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia. Leukemia. 2024. PMID: 38643304. doi:10.1038/s41375-024-02222-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。